At rest, NF-κB stays in the cytoplasm, held back by an inhibitory protein. When the cell detects an alarm signal (bacterial components, cytokines such as TNF-α or tissue damage), that inhibitor is broken down and NF-κB enters the nucleus to activate inflammatory genes.
It is a necessary response for fighting infections and repairing tissue, but its sustained activation is present in chronic inflammation. That is why many anti-inflammatory research lines are measured by their ability to dampen this pathway.
Among research peptides, KPV (the tail end of α-MSH) has been described as an inhibitor of NF-κB signalling in cell models and in experimental colitis, which is the reason for the anti-inflammatory interest in it.
Saying a compound “reduces inflammation” is imprecise. Knowing which pathway it acts on (NF-κB, specific cytokines, melanocortin receptors) makes it possible to compare mechanisms and judge how solid each claim is.
Related terms
Learn it in depth at the Peptide University
- KPV, anti-inflammatory melanocortins and combinations · Module 4
- Wound healing biology: where each peptide acts · Module 4
- Neuroimmunomodulation: VIP, α-MSH, KPV and ARA-290 · Module 12
- Complementary monographs (16–20) · Module 14
Related catalogue compounds
Definition for educational and scientific purposes. It is not medical advice or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).